CN1227230C - Nmda受体配体的前药 - Google Patents

Nmda受体配体的前药 Download PDF

Info

Publication number
CN1227230C
CN1227230C CNB01814361XA CN01814361A CN1227230C CN 1227230 C CN1227230 C CN 1227230C CN B01814361X A CNB01814361X A CN B01814361XA CN 01814361 A CN01814361 A CN 01814361A CN 1227230 C CN1227230 C CN 1227230C
Authority
CN
China
Prior art keywords
compound
formula
benzyl
hydroxy
piperdine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB01814361XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1447793A (zh
Inventor
A·阿兰因
B·布特尔曼
H·菲舍尔
M－P·海茨奈德哈特
J·胡维勒
G·耶施克
E·皮纳尔
R·维勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethiopia Wodtke International Co Ltd
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1447793A publication Critical patent/CN1447793A/zh
Application granted granted Critical
Publication of CN1227230C publication Critical patent/CN1227230C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB01814361XA 2000-08-21 2001-08-20 Nmda受体配体的前药 Expired - Fee Related CN1227230C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
EP00117918.3 2000-08-21

Publications (2)

Publication Number Publication Date
CN1447793A CN1447793A (zh) 2003-10-08
CN1227230C true CN1227230C (zh) 2005-11-16

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB01814361XA Expired - Fee Related CN1227230C (zh) 2000-08-21 2001-08-20 Nmda受体配体的前药

Country Status (35)

Country Link
US (1) US6407235B1 (https=)
EP (1) EP1313703B1 (https=)
JP (1) JP4162991B2 (https=)
KR (1) KR100589991B1 (https=)
CN (1) CN1227230C (https=)
AR (1) AR030373A1 (https=)
AT (1) ATE386022T1 (https=)
AU (2) AU8589401A (https=)
BR (1) BR0113348A (https=)
CA (1) CA2419279C (https=)
CY (1) CY1107937T1 (https=)
CZ (1) CZ303319B6 (https=)
DE (1) DE60132782T2 (https=)
DK (1) DK1313703T3 (https=)
EC (1) ECSP034489A (https=)
EG (1) EG24293A (https=)
ES (1) ES2299508T3 (https=)
HR (1) HRP20030125B1 (https=)
HU (1) HU229802B1 (https=)
IL (1) IL154254A0 (https=)
JO (1) JO2289B1 (https=)
MA (1) MA26947A1 (https=)
MX (1) MXPA03001311A (https=)
MY (1) MY136065A (https=)
NO (1) NO324941B1 (https=)
NZ (1) NZ523990A (https=)
PA (1) PA8525601A1 (https=)
PE (1) PE20020291A1 (https=)
PL (1) PL204215B1 (https=)
PT (1) PT1313703E (https=)
RS (1) RS51467B (https=)
RU (1) RU2272027C2 (https=)
SI (1) SI1313703T1 (https=)
WO (1) WO2002016321A1 (https=)
ZA (1) ZA200300894B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1265864A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
EP1973872A4 (en) 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
PL4001272T3 (pl) 2013-11-05 2025-02-10 Astrazeneca Ab Proleki antagonisty nmda

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
KR100589991B1 (ko) 2006-06-15
US6407235B1 (en) 2002-06-18
JO2289B1 (en) 2005-09-12
CY1107937T1 (el) 2013-09-04
RS51467B (sr) 2011-04-30
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28
HRP20030125A2 (en) 2005-02-28
JP4162991B2 (ja) 2008-10-08
ES2299508T3 (es) 2008-06-01
PE20020291A1 (es) 2002-04-17
DE60132782T2 (de) 2009-02-05
SI1313703T1 (sl) 2008-06-30
CZ303319B6 (cs) 2012-08-01
MY136065A (en) 2008-08-29
PL204215B1 (pl) 2009-12-31
NO20030781D0 (no) 2003-02-19
EP1313703A1 (en) 2003-05-28
AR030373A1 (es) 2003-08-20
KR20030022417A (ko) 2003-03-15
PT1313703E (pt) 2008-03-25
AU2001285894B2 (en) 2006-06-15
EG24293A (en) 2009-01-08
BR0113348A (pt) 2003-07-08
DK1313703T3 (da) 2008-05-19
HRP20030125B1 (en) 2011-07-31
ATE386022T1 (de) 2008-03-15
MXPA03001311A (es) 2003-06-30
EP1313703B1 (en) 2008-02-13
HUP0301548A2 (hu) 2003-08-28
AU8589401A (en) 2002-03-04
IL154254A0 (en) 2003-09-17
DE60132782D1 (de) 2008-03-27
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
CA2419279C (en) 2008-10-14
MA26947A1 (fr) 2004-12-20
CZ2003492A3 (cs) 2004-01-14
NO20030781L (no) 2003-02-19
PA8525601A1 (es) 2002-04-25
JP2004506715A (ja) 2004-03-04
US20020040037A1 (en) 2002-04-04
WO2002016321A1 (en) 2002-02-28
ZA200300894B (en) 2004-04-30
ECSP034489A (es) 2003-03-31
RU2272027C2 (ru) 2006-03-20
CA2419279A1 (en) 2002-02-28
PL361387A1 (en) 2004-10-04
NZ523990A (en) 2004-09-24
CN1447793A (zh) 2003-10-08
HUP0301548A3 (en) 2010-03-29

Similar Documents

Publication Publication Date Title
CN1098262C (zh) 光学活性的哌啶化合物的酸加成盐和其制备方法
CN1662497A (zh) N－[苯基(哌啶－2－基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用
CN1688548A (zh) 喹啉抗生素中间体的制备方法
CN1708481A (zh) 作为抗微生物剂的n－烷基－4－亚甲基氨基－3－羟基－2－吡啶酮
CN1176080C (zh) 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途
CN1044816A (zh) 关于有机化合物的改进
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1178914C (zh) 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇
CN101048157A (zh) 代谢型谷氨酸受体的杂环二氢茚酮增强剂
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1610683A (zh) 作为磷酸酶抑制剂的嘧啶并三嗪
CN1322134A (zh) 作为速激肽受体拮抗剂的萘甲酰胺
CN1956978A (zh) 作为肥大细胞类胰蛋白酶抑制剂的[4－(5－氨基甲基－2－氟－苯基) －哌啶－1－基] －(4－溴－3－甲基－5－丙氧基－噻吩－2－基)-甲酮盐酸盐
CN1206213C (zh) N－芳基磺酰氨基酸ω－酰胺
CN1227230C (zh) Nmda受体配体的前药
CN1170814C (zh) 用于强化胆碱能活性的酰胺化合物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
CN1216526A (zh) 3,4－二取代的苯基乙醇氨基1,2,3,4,－四氢化萘甲酰胺衍生物
CN1142141C (zh) 乙磺酰基哌啶衍生物
CN1742004A (zh) 具有止痛活性的吲唑酰胺类
CN1092074A (zh) 二氮杂䓬衍生物
CN1315951A (zh) Fkbp抑制剂
CN101048392A (zh) 新用途
HK1059083B (en) Prodrugs to nmda receptor ligands
CN1468220A (zh) 新型哌啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059083

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: EVOTEC INTERNATIONAL GMBH

Free format text: FORMER OWNER: F. HOFFMANN-LA ROCHE AG

Effective date: 20130826

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130826

Address after: hamburg

Patentee after: Ethiopia wodtke International Co. Ltd.

Address before: Basel

Patentee before: F. Hoffmann-La Roche AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051116

Termination date: 20150820

EXPY Termination of patent right or utility model